ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment"

  • Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting

    Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico

    Mariangelí Arroyo-Ávila1, Ruth Fred-Jiménez 1, Naydi Pérez-Ríos 1, Noelia Rodríguez 1, Grissel Ríos 1 and Luis Vilá 1, 1University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

    Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
  • Abstract Number: 507 • 2019 ACR/ARP Annual Meeting

    Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Mitsuhiro Rokuda 3, Hiroyuki Izutsu 3, Yuichiro Kaneko 3, Musashi Fukuda 3, Daisuke Kato 3 and Désirée van der Heijde 4, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Astellas Pharma, Inc., Tokyo, Japan, 4Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
  • Abstract Number: 757 • 2019 ACR/ARP Annual Meeting

    Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

    Hajime Yoshifuji1, Haruhito Uchida 2, Yoshikazu Nakaoka 3, Takahiko Sugihara 4, Mitsuaki Isobe 5 and Masayoshi Harigai 6, 1Kyoto University, Kyoto, Japan, 2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Sakakibara Heart Institute, Tokyo, Japan, 6Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Takayasu arteritis (TAK) occurs at a young age and has a long-term clinical course. Progression of arterial stenosis or dilatation leads to organ dysfunction.…
  • Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting

    Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial

    Maxime Verhoeven1, Janneke Tekstra 1, Attila Pethö-Schramm 2, Michelle Borm 3, Jacob van Laar 1, Floris Lafeber 1, Johannes Bijlsma 1, Johannes Jacobs 1 and Paco Welsing 1, 1UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 2Hoffmann-La Roche, Basel, Basel, Switzerland, 3Roche Nederland BV, Woerden, Netherlands

    Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
  • Abstract Number: 2373 • 2019 ACR/ARP Annual Meeting

    Two Decades of Changes in RA Treatment and Disease Outcomes from the United States

    Sofia Pedro1, Alyssa Dominique 2, Rebecca Schumacher 1, Yomei Shaw 1, Kristin Wipfler 1, Teresa Simon 3 and Kaleb Michaud 4, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Bristol-Myers Squibb, Princeton, NJ, 3Bristol-Myers Squibb*, Princeton, NJ, 4FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…
  • Abstract Number: 508 • 2019 ACR/ARP Annual Meeting

    Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

    Tsutomu Takeuchi1, Yoshiya Tanaka 2, Sakae Tanaka 3, Atsushi Kawakami 4, Yeong-Wook Song 5, Yi-Hsing Chen 6, Mitsuhiro Rokuda 7, Hiroyuki Izutsu 7, Satoshi Ushijima 7, Yuichiro Kaneko 7, Yoshihiro Nakashima 7, Teruaki Shiomi 7 and Emi Yamada 7, 1Keio University School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3University of Tokyo, Tokyo, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Seoul National University Hospital, Seoul, Republic of Korea, 6Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 7Astellas Pharma, Inc., Tokyo, Japan

    Background/Purpose: Peficitinib, a novel oral Janus kinase (JAK) inhibitor, demonstrated efficacy and an acceptable safety profile in a Phase 2b study (RAJ1 study, NCT01649999) and…
  • Abstract Number: 766 • 2019 ACR/ARP Annual Meeting

    Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica

    Akiko Aoki1, Hiroshi Kobayashi 1 and Hiroshi Oka 1, 1Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan

    Background/Purpose: Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GC), but relapses and long-term GC therapy are common. 2015 EULAR/ACR recommendations suggest…
  • Abstract Number: 1422 • 2019 ACR/ARP Annual Meeting

    Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA

    Paul Emery1, Yoshiya Tanaka 2, Vivian Bykerk 3, Clifton Bingham 4, Thomas Huizinga 5, Gustavo Citera 6, Sean Connolly 7, Kuan-Hsiang Gary Huang 7, Yedid Elbez 8, Sumanta Mukherjee 7 and Roy Fleischmann 9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Hospital for Special Surgery, New York City, NY, 4Johns Hopkins University, Baltimore, MD, 5Leiden University Medical Center, Leiden, Netherlands, 6Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Bristol-Myers Squibb, Princeton, NJ, 8Excelya, Boulogne-Billancourt, France, 9Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: T-cell profiles are heterogeneous between individuals and consist of naïve T cells, memory T cells (including effector memory T cells [TEM] and central memory…
  • Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting

    Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry

    Dimitrios Pappas1, Taylor Blachley 2, Steve Zlotnick 3, Jennie Best 3, Kelechi Emeanuru 2 and Joel Kremer 4, 1Columbia University, New York, NY, 2Corrona, LLC, Waltham, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
  • Abstract Number: 510 • 2019 ACR/ARP Annual Meeting

    Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels

    Christina Charles-Schoeman1, Thierry Sornasse 2 and Jeremy Sokolove 2, 1University of California, Los Angeles, CA, 2AbbVie Immunology Clinical Development, Redwood City

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory condition associated with increased rates of atherosclerotic progression via pathogenic remodeling of high-density lipoprotein (HDL)-associated proteins, resulting…
  • Abstract Number: 785 • 2019 ACR/ARP Annual Meeting

    Predictors of Response to Tumour Necrosis Factor – α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience

    Muhammad Shipa1, Anastasia-vasiliki Madenidou 2, vera Choida 1, Anna Radziszewska 3, corinne fisher 4, coziana ciurtin 1, maria Leandro 1 and Debajit Sen 1, 1Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, London, United Kingdom, 2Centre for Adolescent Rheumatology, University College London London, UK, LOndon, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology versus Arthritis at UCL, UCLH and GOSH, London, UK, lonodn, United Kingdom

    Background/Purpose: Biologics have transformed the treatment of Juvenile idiopathic arthritis (JIA) and escalation toTumour Necrosis Factor - α inhibitors (TNFi) after failure of methotrexate (MTX)…
  • Abstract Number: 1425 • 2019 ACR/ARP Annual Meeting

    Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial

    Thomas Huizinga1, René Toes 1, Michael Weinblatt 2, Michael Schiff 3, Roy Fleischmann 4, Yedid Elbez 5, Sean Connolly 6, Michael Maldonado 6 and Sheng Gao 6, 1Leiden University Medical Center, Leiden, Netherlands, 2Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, 3University of Colorado, Denver, CO, 4Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 5Excelya, Boulogne-Billancourt, France, 6Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a marker for early, erosive RA.1 In the Abatacept (ABA) versus adaliMumab (ADA) comParison in bioLogic-naïvE RA subjects with…
  • Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting

    Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome

    Toshihisa Kojima1, Masayo Kojima 2, Hajime Ishikawa 3, Sakae Tanaka 4, Nobuhiko Haga 5, Keiichiro Nishida 6, Masao Yukioka 7, Jun Hashimoto 8, Hisaaki Miyahara 9, Yasuo Niki 10, Tomoatsu Kimura 11, Hiromi Oda 12, Shuji Asai 1, Koji Funahashi 13 and Naoki Ishiguro 1, 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Nagoya City University Graduate School of Medicne, Nagoya, Japan, 3Niigata Rheumatic Center, Niigata, Japan, 4University of Tokyo, Tokyo, Japan, 5The University of Tokyo Hospital, Tokyo, Japan, 6Okayama University, Graduate School of Medicine, Okayama, Japan, 7Yukioka Hospital, Osaka, Japan, 8National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, 9National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, 10Keio University, School of Medicine, Tokyo, Japan, 11University of Toyama, Faculty of Medicine, Toyama, Japan, 12Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 13Kariya-Toyota General Hosptal, Kariya, Japan

    Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
  • Abstract Number: 513 • 2019 ACR/ARP Annual Meeting

    Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

    Josef Smolen1, Paul Emery 2, William Rigby 3, Yoshiya Tanaka 4, Juan Ignacio Vargas 5, Nemanja Damjanov 6, Manish Jain 7, Yunxia Sui 8, Jose Jeffrey Enejosa 9, Aileen Pangan 10, Heidi Camp 9 and Stanley Cohen 11, 1Medical University of Vienna, Vienna, Austria, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 3Dartmouth-Hitchcock Medical Center, Lebanon, 4University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 5Quantum Research, Puerto Varas, Chile, 6Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, Belgrade, Serbia, 7Rheumatology, Great Lakes Clinical Trials, Great Lakes, 8AbbVie Inc., Chicago, 9AbbVie Inc., North Chicago, IL, 10AbbVie Inc., North Chicago, 11Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In the SELECT-MONOTHERAPY trial, upadacitinib (UPA), an oral JAK1-selective inhibitor, showed efficacy when used as monotherapy over 14 weeks (wks) in rheumatoid arthritis (RA)…
  • Abstract Number: 848 • 2019 ACR/ARP Annual Meeting

    Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis

    Michael George1, Joshua Baker 2, Kevin Winthrop 3, Qufei Wu 2, Lang Chen 4, Fenglong Xie 5, Huifeng Yun 4 and Jeffrey Curtis 4, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA, 3Oregon Health and Science University, Portland, OR, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham

    Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 22
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology